<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490437</url>
  </required_header>
  <id_info>
    <org_study_id>UOSG-AMC-0804</org_study_id>
    <nct_id>NCT01490437</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma</brief_title>
  <acronym>PECULIAR</acronym>
  <official_title>A Prospective Phase 2 Study of PEmetrexed in Combination With Cisplatin in Patients With Advanced UrotheLIal CAnceR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pemetrexed has demonstrated a favorable response with minimal toxicity when used as single
      agent as first-line and second-line treatment for advanced urothelial carcinoma. The response
      rates were 32% and 28% for the first-line and second-line setting, respectively. Cisplatin is
      one the most active chemotherapeutic agents in urothelial cancer, frequently used as
      combination chemotherapy such as GP (gemcitabine plus cisplatin) or MVAC (methotrexate,
      vinblastine, adriamycin, and cisplatin).

      Pemetrexed and cisplatin showed favorable activity profile in advanced non-small cell lung
      cancer with highly favorable toxicity profile.

      This study is to assess the efficacy and safety of pemetrexed plus cisplatin in advanced
      urothelial carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Based on RECIST v.1.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>8 months</time_frame>
    <description>Based on NCI CTCAE v.3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>PemCis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed plus Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks</description>
    <arm_group_label>PemCis</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days</description>
    <arm_group_label>PemCis</arm_group_label>
    <other_name>cisplan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks</description>
    <arm_group_label>PemCis</arm_group_label>
    <other_name>Dexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamins</intervention_name>
    <description>Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7</description>
    <arm_group_label>PemCis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of urothelial (transitional cell) carcinoma with the
             exception of micropapillary subtype

          -  Patients must have recurrent disease (locally advanced or metastatic) that is not
             amenable to local therapy or newly diagnosed distant metastatic disease

          -  Measurable disease defined by RECIST v.1.0

          -  ECOG performance status of 2 or better

          -  Adequate organ and bone marrow function defined as

        Exclusion Criteria:

          -  Other tumor type than urothelial carcinoma

          -  Presence or history of CNS metastasis

          -  Prior systemic chemotherapy or immunotherapy (but prior local intravesical
             chemotherapy or immunotherapy was allowed. And recurrent disease after adjuvant or
             neoadjuvant cisplatin-based systemic chemotherapy is allowed if the last chemotherapy
             was administered 1 year or more before the patient enrollment.)

          -  Presence of second primary malignancy (except in situ carcinoma of the cervix or
             adequately treated basal cell carcinoma of the skin)

          -  Peripheral sensory neuropathy grade 2 or worse

          -  Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JLee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Advanced urothelial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

